Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) EBIT: 2013-2025

Historic EBIT for MediWound (MDWD) over the last 13 years, with Sep 2025 value amounting to -$6.5 million.

  • MediWound's EBIT fell 28.42% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.6 million, marking a year-over-year decrease of 37.07%. This contributed to the annual value of -$19.4 million for FY2024, which is 26.88% down from last year.
  • According to the latest figures from Q3 2025, MediWound's EBIT is -$6.5 million, which was down 14.15% from -$5.7 million recorded in Q2 2025.
  • MediWound's EBIT's 5-year high stood at $2.1 million during Q4 2022, with a 5-year trough of -$6.5 million in Q3 2025.
  • Moreover, its 3-year median value for EBIT was -$4.5 million (2024), whereas its average is -$4.7 million.
  • In the last 5 years, MediWound's EBIT surged by 160.30% in 2022 and then tumbled by 283.42% in 2023.
  • Over the past 5 years, MediWound's EBIT (Quarterly) stood at -$3.5 million in 2021, then soared by 160.30% to $2.1 million in 2022, then slumped by 283.42% to -$3.9 million in 2023, then plummeted by 56.68% to -$6.1 million in 2024, then decreased by 28.42% to -$6.5 million in 2025.
  • Its EBIT was -$6.5 million in Q3 2025, compared to -$5.7 million in Q2 2025 and -$5.2 million in Q1 2025.